Metamark Genetics snags potential $365m cancer targets deal with Janssen
This article was originally published in Clinica
Executive Summary
Metamark Genetics has linked up with Janssen Biotech (Johnson & Johnson) in a deal designed to identify cancer targets based on Metamark's discovery platform, Prognosis Determinants, that looks at how tumours progress.